Udenyca Well Prepared to Meet Market Demand
Coherus BioSciences, Inc., has announced that its United States manufacturing and distribution is well positioned to
ensure uninterrupted availability of Udenyca® (pegfilgrastim-cbqv)
for patients. Coherus does not source active pharmaceutical ingredients for Udenyca®
from China, or India, and its manufacturing site in Boulder, Colorado has not been impacted by coronavirus, the company said in a statement.
Read the company statement